Revlon investment
This article was originally published in The Rose Sheet
Executive Summary
Board of directors approves $150 mil. cash investment proposed by MacAndrews & Forbes following review by special committee. MacAndrews & Forbes also agrees to continue commitment to provide Revlon with additional cash infusion of up to $40 mil. through December 2003 and up to $65 mil. through December 2004 in the form of a senior unsecured line of credit. Revlon also received necessary amendment to its credit facility to complete the transactions, firm adds. Company has obtained a waiver to its EBITDA and certain other financial covenants for the fourth quarter of 2002, elimination of such covenants for the first three quarters of 2003 and a waiver of the fourth quarter 2003 financial covenants through Jan. 31, 2004. Revlon announced it had been offered the original cash infusion in December (1"The Rose Sheet" Dec. 23, 2002, p. 3)...
You may also be interested in...
Revlon Boosted Marketing, Product Cuts To Follow $150 Mil. Investment
Revlon plans to accelerate several elements of its growth strategy using $150 mil. in cash from a funding proposal by investment firm MacAndrews & Forbes, which is wholly-owned by Revlon's majority investor, Chairman Ronald Perelman, the company announced Dec. 18
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.